Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
Top Cited Papers
- 1 May 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (9) , 1746-1751
- https://doi.org/10.1200/jco.2003.09.027
Abstract
Purpose: To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients and Methods: Forty-four previously untreated patients with CLL/SLL received rituximab 375 mg/m2 weekly for 4 consecutive weeks. All patients were required to have one or more indications for treatment. Patients with objective response or stable disease continued to receive identical 4-week rituximab courses at 6-month intervals, for a total of four courses. Results: The objective response rate after the first course of rituximab was 51% (4% complete responses). Twenty-eight patients received one or more additional courses of rituximab. At present, the overall response rate is 58%, with 9% complete responses. After a median follow-up of 20 months, the median progression-free survival (PFS) time was 18.6 months, and the 1- and 2-year PFS rates were...Keywords
This publication has 17 references indexed in Scilit:
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arraysBlood, 2001
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable ToxicityJournal of Clinical Oncology, 2001
- Rituximab Dose-Escalation Trial in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996
- Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAmerican Journal of Hematology, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958